Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated ...
Nasdaq16d
Foghorn Therapeutics Continues Enrollment in Phase 1 Trial of First-in-Class SMARCA2 Inhibitor FHD-909 for NSCLC and Reports Strong Financial Outlook
The company has also achieved selective degradation of ARID1B and plans to provide updates on this and other programs, including selective CBP and EP300 degraders, in 2025. Foghorn reported a ...